Patient adherence to osteoporosis medications: Problems, consequences and management strategies

Drugs and Aging

Volumn 24, Issue 1, 2007, Pages 37-55

  Papaioannou, Alexandra ^a,b,d   Kennedy, Courtney C ^a   Dolovich, Lisa ^a,b,c   Lau, Elaine ^a,b,c   Adachi, Jonathan D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Team for Individualizing Pharmacotherapy in Primary Care for Senior (TIPPS)   (Canada)

^c CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; HORMONE; IBANDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ADJUVANT THERAPY; BLOATING; BLOOD CLOTTING; BONE DENSITY; BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSMENORRHEA; EXERCISE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HORMONAL THERAPY; HOSPITALIZATION; HOT FLUSH; HUMAN; LEG CRAMP; MEDICAL LITERATURE; MENOPAUSE; MENSTRUATION; META ANALYSIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; OSTEOPOROSIS; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STOMACH PAIN; SWELLING; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; WEIGHT GAIN;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MICRONUTRIENTS; OSTEOPOROSIS; PATIENT COMPLIANCE; RALOXIFENE; VITAMIN D;

EID: 33846449098     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724010-00003     Document Type: Review

References (94)

1. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991; 90 (1): 107-110
2. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999; 10 (4): 259-64
3. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005; 16 Suppl. 2: S3-7
4. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35 (2): 375-82
5. Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000; 29 (4): 228-51
6. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19 (6): 893-9
7. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12 (12): 989-95
8. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20 (7): 1185-94
9. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone 2004; 35 (5): 1029-37
10. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12 (1): 24-35
11. Ross PD. Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med 1996; 156 (13): 1399-411
12. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151 (10): 2026-32
13. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002
14. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23 (4): 570-8
15. Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005; 6: 39
16. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353 (5): 487-97
17. Sackett DL. Introduction. In: Sackett DL, editor. Compliance with therapeutic regimens. Baltimore (MD): Johns Hopkins University Press, 1976
18. Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005; 4: CD000011
19. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60 (7): 657-65
20. Cranney A, Tugwell P, Wells G, et al. Meta-analyses of therapies for postmenopausal osteoporosis: I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002; 23 (4): 496-507
21. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis: III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23 (4): 517-23
22. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23 (4): 508-16
23. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001; 12 (2): 140-51
24. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis: IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23 (4): 524-8
25. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33
26. Cranney A, Wells GA. Hormone replacement therapy for postmenopausal osteoporosis. Clin Geriatr Med 2003; 19 (2): 361-70
27. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15 (12): 1003-8
28. Goettsch WG, Penning F, Erkens JE, et al. Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fractures [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S278
29. Weycker D, Macarios D, Oster G. Adherence with drug therapy and risk of fracture among women with postmenopausal osteoporosis [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S383
30. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2005; 38 (6): 922-8
31. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study [abstract]. Calcif Tissue Int 2003, 72
32. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14 (12): 965-8
33. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11 (1): 83-91
34. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348 (9041): 1535-41
35. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333 (22): 1437-43
36. Ho AY, Kung AW. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 2005; 39 (9): 1428-33
37. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999; 282 (7): 637-45
38. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288 (1): 49-57
39. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348 (9024): 383-6
40. Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987; 8 (1): 12-9
41. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115 (3): 209-16
42. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003; 14 (3): 259-62
43. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5 (12): 859-62
44. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17 (6): 914-21
45. Zanchetta J, Hakim C, Lombas C. Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Current Therapeutic Research 2004; 6: 470-80
46. Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003; 14 (10): 808-13
47. Steel SA, Albertazzi P, Howarth EM, et al. Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis. Climacteric 2003; 6 (2): 96-103
48. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 1998; 4 (5): 488-92
49. Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26 (2): 245-56
50. Carnevale V, Nieddu L, Romagnoli E, et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int 2005; 17 (3): 478-83
51. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21 (9): 1453-60
52. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48 (3): 271-87
53. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl.): S1-34
54. Eli Lilly and Company. About taking EVISTA [online]. Available from URL: http://www.evista.com [Accessed 2006 Mar 16]
55. Aki S, Eskiyurt N, Akarirmak U, et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J 2003; 44 (6): 961-7
56. Lombas C, Hakim C, Zanchetta J. Compliance with alendronate treatment in an osteoporosis clinic [abstract]. J Bone Miner Res 2001; 15: S529
57. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999; 6 (4): 282-9
58. den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000; 95 (4): 507-12
59. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165 (20): 2414-9
60. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80 (7): 856-61
61. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000 Dec; 22 (12): 1433-42
62. Rizzoli R, Greenspan SL, Bone G, et al. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17 (11): 1988-96
63. Rizzoli R. Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res 2006; 443: 61-5
64. Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003; 14 (5): 437-41
65. Kendler D, Kung AW, Fuleihan G, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48 (3): 243-51
66. Weiss M, Vered I, Foldes AJ, et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 2005; 17 (2): 143-9
67. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24 (11): 1871-86
68. Roche. FDA approves once-monthly Boniva for osteoporosis [online]. Available from URL: http://www.roche.com/medcor-2005-03-29 [Accessed 2006 Oct 23]
69. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006 May; 65 (5): 654-61
70. Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21 (3): 391-401
71. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006; 38 (4 Suppl. 1): S2-6
72. Emkey R. BNSLRC. BALTO I: women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S416
73. Blalock SJ, DeVellis BM, Patterson CC, et al. Effects of an osteoporosis prevention program incorporating tailored educational materials. Am J Health Promot 2002; 16 (3): 146-56
74. Chapurlat RD, Cummings SR. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness? Osteoporos Int 2002; 13 (9): 738-44
75. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89 (3): 1117-23
76. Rijcken CA, Tobi H, Vergouwen AC, et al. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data. Pharmacoepidemiol Drug Saf 2004; 13 (6): 365-70
77. Pilon D, Castilloux AM, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001; 97 (1): 97-100
78. Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol 2004; 11 (2): e267-73
79. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288 (4): 462-7
80. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension 1980; 2 (6): 757-64
81. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24 (1): 67-74
82. Royal Pharmaceutical Society of Great Britain. From compliance to concordance: towards shared goals in medicine taking. London: Royal Pharmaceutical Society of Great Britain, 1997
83. MacLaughlin EJ, MacLaughlin AA, Snella KA, et al. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 2005; 25 (3): 379-86
84. Elliott ME, Meek PD, Kanous NL, et al. Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother 2002; 36 (4): 571-7
85. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337 (10): 670-6
86. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354 (7): 669-83
87. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19 (3): 370-8
88. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330 (7498): 1003
89. Prince RL, Devine A, Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006; 166 (8): 869-75
90. Mastaglia SR, Pellegrini GG, Mandalunis PM, et al. Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats. Bone 2006; 39 (4): 837-44
91. Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996; 51 (2): 145-7
92. French MR, Moore K, Vernace-Inserra F, et al. Factors that influence adherence to calcium recommendations. Can J Diet Pract Res 2005; 66 (1): 25-9
93. Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163 (18): 2165-72
94. Papaioannou A, Giangregorio L, Kvern B, et al. The osteoporosis care gap in Canada. BMC Musculoskelet Disord 2004; 5: 11